



National Securities Market Commission
Markets Directorate General
C/ Edison núm. 4
28006 Madrid

Colmenar Viejo (Madrid), June 3, 2019

Pursuant to Article 17 of Regulation (EU) n° 596/2014 on market abuse and Article 226 of the consolidated text of the Spanish Securities Market Act, approved by Royal Legislative Decree 4/2015, of 23 October, we hereby make the following **REGULATORY ANNOUNCEMENT**:

“In relation to Significant Fact n° 278.775 dated June 1st, 2019, Pharma Mar announces that it will hold a conference call with investors on June 4th at 07:00 CST (14:00 CET) to discuss the positive results of the Phase II trial with lurbinectedin for the treatment of relapsed small cell lung cancer, recently presented at ASCO (American Society of Clinical Oncology) by Dr. Luis Paz-Ares. This teleconference will be attended by Dr. Luis Paz-Ares, Head of the Oncology Department at the Hospital Universitario 12 de Octubre in Madrid and main author of the study. The teleconference will take place on June 4th at 07:00 CST (14:00 CET). The numbers to connect to the teleconference are 877-407-3102 (from USA or Canada), 201-493-6790 (other countries) and 900 834 236 for Spain. Interested parties can also follow the conference call and see the accompanying slides live via the following link:

<https://78449.themediaframe.com/dataconf/productusers/phm/mediaframe/30603/index.html>

The recording of the teleconference can be accessed on PharmaMar's website by visiting the Events Calendar section of the Company's website www.pharmamar.com.”

Pharma Mar S.A.
Avda. de los Reyes, 1
P.I. La Mina
28770 Colmenar Viejo
(Madrid) Spain
www.pharmamar.com